SCHEMBL61731

SCHEMBL61731

NC(=O)C1CCC(N)CC1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.43
KMT2A Q03164 2/20 0.39
KDM4E B2RXH2 2/20 0.39
MAPT P10636 1/20 0.39
ATM Q13315 1/20 0.39
CYP2D6 P10635 1/20 0.39
GAA P10253 1/20 0.38
NOS2 P35228 1/20 0.36
CYP3A4 P08684 1/20 0.33
MEN1 O00255 1/20 0.33
APEX1 P27695 1/20 0.33
TDP1 Q9NUW8 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
ALDH1A1 P00352 1/20 0.33
TSHR P16473 1/20 0.33
PLG P00747 1/20 0.32
PLAT P00750 1/20 0.32
LMNA P02545 1/20 0.32
EPHX1 P07099 1/20 0.32
SMYD3 Q9H7B4 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL482012 1.00 SMN1; SMN2 (0.43) SMN1; SMN2KMT2AKDM4EMAPTATM
SCHEMBL8228115 1.00 SMN1; SMN2 (0.43) SMN1; SMN2KMT2AKDM4EMAPTATM
Hydrochloric Acid SCHEMBL4928769 0.97 SMN1; SMN2 (0.41) SMN1; SMN2KMT2AKDM4EMAPTATM
Hydrochloric Acid SCHEMBL3938698 0.97 SMN1; SMN2 (0.41) SMN1; SMN2KMT2AKDM4EMAPTATM
Hydrochloric Acid SCHEMBL3401056 0.97 SMN1; SMN2 (0.41) SMN1; SMN2KMT2AKDM4EMAPTATM
Hydrochloric Acid SCHEMBL14311831 0.97 SMN1; SMN2 (0.41) SMN1; SMN2KMT2AKDM4EMAPTATM
SCHEMBL23625187 0.90 KDM4E (0.43) SMN1; SMN2KMT2AKDM4EMAPTATM
Cyclopropanecarboxylic Acid Amide SCHEMBL5661 0.87
Cyclopropanecarboxylic Acid Amide SCHEMBL6927157 0.87 SMN1; SMN2 (0.50) SMN1; SMN2KMT2AKDM4EMAPTATM
SCHEMBL28418543 0.87 SMN1; SMN2 (0.50) SMN1; SMN2KMT2AKDM4EMAPTATM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 268 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11884678-B2 Method for producing a spirooxindole derivative DAIICHI SANKYO COMPANY, LIMITED (JP) 2024-01-30 US claimed
US-11724999-B2 Inhibitors of RAS-effector protein interactions OXFORD UNIVERSITY INNOVATION LIMITED (GB) 2023-08-15 US claimed
US-20210047305-A1 INHIBITORS OF RAS-EFFECTOR PROTEIN INTERACTIONS OXFORD UNIVERSITY INNOVATION LIMITED (GB) 2021-02-18 US claimed
EP-3743414-A1 INHIBITORS OF RAS-EFFECTOR PROTEIN INTERACTIONS Oxford University Innovation Limited (GB) 2020-12-02 EP claimed
WO-2019145719-A1 INHIBITORS OF RAS-EFFECTOR PROTEIN INTERACTIONS OXFORD UNIVERSITY INNOVATION LIMITED (GB) 2019-08-01 WO claimed
EP-2763990-B1 PYRROLOPYRAZINE KINASE INHIBITORS HOFFMANN LA ROCHE (CH) 2017-02-22 EP claimed
EP-2771340-B1 6-(4-HYDROXY-PHENYL)-1H-PYRAZOLO[3,4-B]PYRIDINE-4-CARBOXYLIC ACID AMIDE DERIVATIVES AS KINASE INHIBITORS SANOFI SA (FR) 2016-04-13 EP claimed
EP-2079727-B1 KINASE INHIBITOR COMPOUNDS XCOVERY INC (US) 2016-02-17 EP claimed
EP-2771340-A1 6-(4-HYDROXY-PHENYL)-1H-PYRAZOLO[3,4-B]PYRIDINE-4-CARBOXYLIC ACID AMIDE DERIVATIVES AS KINASE INHIBITORS SANOFI (FR) 2014-09-03 EP claimed
US-8658646-B2 Pyrrolopyrazine kinase inhibitors HOFFMANN-LAROCHE INC. (US) 2014-02-25 US claimed
WO-2008033562-A2 KINASE INHIBITOR COMPOUNDS XCOVERY, INC. (US) 2008-03-20 WO claimed
EP-1751151-A1 PYRAZOLO '3,4-B! PYRIDINE COMPOUNDS, AND THEIR USE AS PHOSPHODIESTERASE TYPE 4 (PDE4) INHIBITORS GLAXO GROUP LIMITED (GB) 2007-02-14 EP claimed
EP-1740590-A1 PYRAZOLO [3,4- b] PYRIDINE COMPOUNDS, AND THEIR USE AS PDE4 INHIBITORS GLAXO GROUP LIMITED (GB) 2007-01-10 EP claimed
WO-2006130673-A1 3-BENZOIMIDAZOLYL-PYRAZOLOPYRIDINES USEFUL IN TREATING KINASE DISORDERS JANSSEN PHARMACEUTICA, N.V. (BE) 2006-12-07 WO claimed
EP-1628619-A2 4-AMINOPYRIMIDINE-5-ONE F.HOFFMANN-LA ROCHE AG (CH) 2006-03-01 EP claimed
WO-2005090354-A1 PYRAZOLO[3,4-b] PYRIDINE COMPOUNDS, AND THEIR USE AS PDE4 INHIBITORS GLAXO GROUP LIMITED (GB) 2005-09-29 WO claimed
WO-2005090348-A1 PYRAZOLO ’3,4-B! PYRIDINE COMPOUNDS, AND THEIR USE AS PHOSPHODIESTERASE TYPE 4 (PDE4) INHIBITORS GLAXO GROUP LIMITED (GB) 2005-09-29 WO claimed
US-20040162303-A1 4-aminopyrimidine-5-one derivatives BARTKOVITZ DAVID JOSEPH (US) 2004-08-19 US claimed
WO-2004069139-A2 4-AMINOPYRIMIDIN-5-YL-METHANONE DERIVATIVES FOR INHIBITION OF CDK4 ACTIVITY F.HOFFMANN-LA ROCHE AG (CH) 2004-08-19 WO claimed
WO-1992002543-A1 NOVEL IMMUNOSUPPRESSANT PEPTIDES CYTEL CORPORATION (US) 1992-02-20 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11884678-B2 Method for producing a spirooxindole derivative MDM2, TP53, RB1 SMN1; SMN2 4855/4885KMT2A 2863/4885KDM4E 3908/4885
US-20040162303-A1 4-aminopyrimidine-5-one derivatives CDK4, CDKL4, CDK6 SMN1; SMN2 2994/4885KMT2A 750/4885KDM4E 191/4885
US-20210047305-A1 INHIBITORS OF RAS-EFFECTOR PROTEIN INTERACTIONS KRAS, NRAS, HRAS SMN1; SMN2 4044/4885KMT2A 3937/4885KDM4E 2955/4885
US-11724999-B2 Inhibitors of RAS-effector protein interactions KRAS, NRAS, HRAS SMN1; SMN2 4044/4885KMT2A 3937/4885KDM4E 2955/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.